Skip to main content
. 2022 Oct 20;14(20):5148. doi: 10.3390/cancers14205148

Figure 1.

Figure 1

METTL3 expression in PCa patients. Bioinformatic analysis using multiple PCa datasets from the cBioPortal revealed METTL3 is altered in PCa (z score threshold ±1) (A,B). METTL3 expression was investigated further in normal and primary tumour specimens (C) and between patients without or with BCR (D) in the TCGA cohort using UCSC Xena. IHC analysis in prostate specimens identified a range of METTL3 protein expression in non-malignant (E–G) and tumour (H–J) specimens. A comparison of non-malignant and tumour METTL3 expression identified higher expression in tumour specimens (K). Adeno = adenocarcinoma, NEPC = neuroendocrine PCa.